Mangalam Drugs and Organics Ltd
BSE:532637
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Mangalam Drugs and Organics Ltd
Operating Income
Mangalam Drugs and Organics Ltd
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Mangalam Drugs and Organics Ltd
NSE:MANGALAM
|
Operating Income
-₹168.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Operating Income
₹63.2B
|
CAGR 3-Years
10%
|
CAGR 5-Years
14%
|
CAGR 10-Years
10%
|
|
|
Cipla Ltd
NSE:CIPLA
|
Operating Income
₹53.3B
|
CAGR 3-Years
15%
|
CAGR 5-Years
12%
|
CAGR 10-Years
9%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Operating Income
₹135.6B
|
CAGR 3-Years
42%
|
CAGR 5-Years
18%
|
CAGR 10-Years
10%
|
|
|
Lupin Ltd
NSE:LUPIN
|
Operating Income
₹59.6B
|
CAGR 3-Years
147%
|
CAGR 5-Years
32%
|
CAGR 10-Years
8%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Operating Income
₹33.6B
|
CAGR 3-Years
19%
|
CAGR 5-Years
13%
|
CAGR 10-Years
4%
|
|
Mangalam Drugs and Organics Ltd
Glance View
Mangalam Drugs & Organics Ltd. engages in the manufacture of drugs, medicines and allied products. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2005-05-26. The firm handles marketing in both domestic and export markets. The firm is also engaged in the Fight Malaria program for the supply of anti-malarial APIs worldwide. Its API products include Acyclovir, Amodiaquine HCI, Artemether, Artesunate, Atazanavir Sulfate, Atorvastatin Calcium, Bisoprolol Fumarate and Furosemide. Its intermediates products include 4,6-Dichloro-5-Methoxy Pyrimidine, 2-Dibutylamino-1-Ethanol (DBA), 4,7- Dichloroquinoline, Ortho Phenoxy Methane Sulfonanilide, Tenofovir Alafenamide Base and Tenofovir Disoproxil Base. The company also offers specialty chemicals, such a L (+)-Menthol, 2,3 Dihydrophthalazine-1,4-dione, 4-Cynoethyl-2- Methyl Phenol. The firm offers its products to Italy, Russia, China, Turkey, Nigeria, Uganda, Kenya and Pakistan. The company has two multi-product manufacturing facilities located at Vapi, district Valsad, Gujarat.
See Also
What is Mangalam Drugs and Organics Ltd's Operating Income?
Operating Income
-168.6m
INR
Based on the financial report for Dec 31, 2025, Mangalam Drugs and Organics Ltd's Operating Income amounts to -168.6m INR.
